Pharmacokinetics and Drug Interactions of Cholinesterase Inhibitors Administered in Alzheimer's Disease
Author:
- M. Lynn CrismonMCM. Lynn Crismon
- 4 March 1998
- journal article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 18 (2P2) , 47-54
Abstract
Cholinesterase inhibitors are the first agents to be successfully developed specifically for the treatment of cognitive decline associated with Alzheimer's disease. Basic knowledge of their pharmacokinetics is important to their appropriate administration. Their pharmacokinetics help determine the magnitude and duration of their pharmacologic effects, and also the manner in which they affect the degree of cholinesterase inhibition and recovery. The clinical utility of measuring these values in daily practice awaits further research. Drug interactions with cholinesterase inhibitors may occur by pharmacokinetic or pharmacodynamic mechanisms. For the most part, interactions that are mediated by the hepatic cytochrome P‐450 system have been inadequately evaluated.Keywords
This publication has 26 references indexed in Scilit:
- Metrifonate and dichlorvos: Effects of a single oral administration on cholinesterase activity in rat brain and bloodNeurochemical Research, 1996
- Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's diseaseLife Sciences, 1996
- Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease*Clinical Pharmacology & Therapeutics, 1995
- Relationship Between Pharmacokinetics and Pharmacodynamics of Eptastigmine in Young Healthy VolunteersThe Journal of Clinical Pharmacology, 1995
- A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesteraseLife Sciences, 1994
- The Temporal Effect of Food on Tacrine BioavailabilityThe Journal of Clinical Pharmacology, 1994
- A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's DiseaseJAMA, 1994
- Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjectsEuropean Journal of Clinical Pharmacology, 1993
- Comparison of the Pharmacokinetics of E2020, A New Compound for Alzheimer's Disease, in Healthy Young and Elderly SubjectsThe Journal of Clinical Pharmacology, 1993
- Effects of metrifonate, a long‐acting cholinesterease inhibitor, in alzheimer disease: Report of an open trialDrug Development Research, 1990